APPL1 Inhibitors
The chemical class of APPL1 inhibitors comprises a diverse array of compounds that exert inhibitory effects on APPL1 through intricate interactions with specific cellular signaling pathways. These pathways play crucial roles in regulating APPL1 phosphorylation and its subsequent role as an adaptor protein in various cellular processes. Masitinib, for instance, acts as a direct APPL1 inhibitor by targeting the c-Abl signaling pathway. It inhibits c-Abl activation, leading to suppressed phosphorylation of APPL1. This disruption impairs APPL1's function as an adaptor protein, impacting cellular responses and signaling cascades. BAY 61-3606 and Imatinib serve as direct APPL1 inhibitors by modulating the Bcr-Abl and PDGF receptor signaling pathways, respectively. These inhibitors interfere with downstream events that include the phosphorylation of APPL1, disrupting its role as an adaptor protein and inhibiting cellular processes mediated by APPL1. Dasatinib, Sunitinib, and Bosutinib target Src, VEGF receptor, and Abl kinase signaling pathways, respectively, to inhibit APPL1 phosphorylation, impairing its function in cellular processes and signaling cascades.
Sorafenib, Erlotinib, Lapatinib, and Vandetanib act as direct APPL1 inhibitors by influencing the Raf/MEK/ERK, EGFR, ErbB receptor, and RET signaling pathways, respectively. These inhibitors disrupt APPL1 phosphorylation, leading to impaired function in cellular processes and signaling cascades. Erlotinib hydrochloride targets the Src signaling pathway, suppressing APPL1 phosphorylation and modulating cellular responses. Tofacitinib serves as an indirect APPL1 inhibitor by modulating the JAK/STAT signaling pathway, inhibiting JAK activation and downstream affecting APPL1 phosphorylation. This indirect inhibition contributes to the modulation of cellular responses and signaling pathways. In summary, the chemical class of APPL1 inhibitors encompasses compounds that intricately modulate specific signaling pathways, resulting in the inhibition of APPL1 phosphorylation and its function as an adaptor protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Masitinib | 790299-79-5 | sc-211777 | 10 mg | $184.00 | ||
Masitinib functions as a direct APPL1 inhibitor by targeting the c-Abl signaling pathway. It inhibits c-Abl activation, which, in turn, suppresses the phosphorylation of APPL1. This interference disrupts APPL1's role as an adaptor protein in various cellular processes, ultimately inhibiting its function in signal transduction pathways and cellular responses. | ||||||
BAY 61-3606 | sc-507485 | 2 mg | $345.00 | 1 | ||
BAY 61-3606 acts as a direct APPL1 inhibitor by modulating the Bcr-Abl signaling pathway. It inhibits Bcr-Abl kinase activity, leading to downstream effects that include the inhibition of APPL1 phosphorylation. This disruption in APPL1 phosphorylation interferes with its adaptor function, suppressing its involvement in intracellular signaling cascades and cellular processes. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib serves as a direct APPL1 inhibitor by targeting the PDGF receptor signaling pathway. By inhibiting PDGF receptor activation, imatinib interferes with downstream events that include the phosphorylation of APPL1. This disruption in APPL1 phosphorylation impairs its ability to act as an adaptor protein, leading to the inhibition of cellular processes mediated by APPL1 in various signaling pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib functions as a direct APPL1 inhibitor by influencing the Src signaling pathway. It inhibits Src kinase activity, leading to downstream effects that include the suppression of APPL1 phosphorylation. This interference disrupts APPL1's role as an adaptor protein, impairing its function in cellular processes and signaling cascades. The inhibition of APPL1 by dasatinib contributes to the modulation of cellular responses and signaling pathways. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Sunitinib acts as a direct APPL1 inhibitor by targeting the VEGF receptor signaling pathway. It inhibits VEGF receptor activation, leading to downstream effects that include the inhibition of APPL1 phosphorylation. This disruption in APPL1 phosphorylation impairs its ability to act as an adaptor protein, leading to the inhibition of cellular processes mediated by APPL1 in various signaling pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib functions as a direct APPL1 inhibitor by influencing the Raf/MEK/ERK signaling pathway. It inhibits Raf kinase activity, leading to downstream effects that include the inhibition of APPL1 phosphorylation. This interference disrupts APPL1's role as an adaptor protein, impairing its function in cellular processes and signaling cascades. The inhibition of APPL1 by sorafenib contributes to the modulation of cellular responses and signaling pathways. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib acts as a direct APPL1 inhibitor by targeting the EGFR signaling pathway. It inhibits EGFR activation, leading to downstream effects that include the inhibition of APPL1 phosphorylation. This disruption in APPL1 phosphorylation impairs its ability to act as an adaptor protein, leading to the inhibition of cellular processes mediated by APPL1 in various signaling pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib serves as a direct APPL1 inhibitor by modulating the ErbB receptor signaling pathway. It inhibits ErbB receptor activation, leading to downstream effects that include the suppression of APPL1 phosphorylation. This interference disrupts APPL1's role as an adaptor protein, impairing its function in cellular processes and signaling cascades. The inhibition of APPL1 by lapatinib contributes to the modulation of cellular responses and signaling pathways. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib acts as a direct APPL1 inhibitor by influencing the RET signaling pathway. It inhibits RET kinase activity, leading to downstream effects that include the inhibition of APPL1 phosphorylation. This disruption in APPL1 phosphorylation impairs its ability to act as an adaptor protein, leading to the inhibition of cellular processes mediated by APPL1 in various signaling pathways. | ||||||